BRPI0805841A2 - agente para tratamento de esclerose múltipla - Google Patents

agente para tratamento de esclerose múltipla Download PDF

Info

Publication number
BRPI0805841A2
BRPI0805841A2 BRPI0805841-5A BRPI0805841A BRPI0805841A2 BR PI0805841 A2 BRPI0805841 A2 BR PI0805841A2 BR PI0805841 A BRPI0805841 A BR PI0805841A BR PI0805841 A2 BRPI0805841 A2 BR PI0805841A2
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment agent
agent
treatment
sclerosis treatment
Prior art date
Application number
BRPI0805841-5A
Other languages
English (en)
Inventor
Masaki Yamabi
Yuchiro Tabunoki
Toshiyuki Edano
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of BRPI0805841A2 publication Critical patent/BRPI0805841A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

AGENTE PARA TRATAMENTO DE ESCLEROSE MúLTIPLA. é descrito um agente oralmente administrável para prevenção e/ou tratamento de esclerose múltipla, que é altamente eficaz para esclerose múltipla e excelente na segurança. Especificamente descrito é um agente para prevenção e/ou tratamento de esclerose múltipla, que contém 2-benzil-5-(4-clorofenil)-6-[4-(metiltio)fenil]-2H-piridazin-3-ona ou um solvato do mesmo como um ativo ingrediente.
BRPI0805841-5A 2007-01-29 2008-01-28 agente para tratamento de esclerose múltipla BRPI0805841A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007017328 2007-01-29
PCT/JP2008/000099 WO2008093495A1 (ja) 2007-01-29 2008-01-28 多発性硬化症治療剤

Publications (1)

Publication Number Publication Date
BRPI0805841A2 true BRPI0805841A2 (pt) 2011-08-30

Family

ID=39673809

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0805841-5A BRPI0805841A2 (pt) 2007-01-29 2008-01-28 agente para tratamento de esclerose múltipla

Country Status (12)

Country Link
US (1) US20100075972A1 (pt)
EP (1) EP2127653A1 (pt)
JP (1) JPWO2008093495A1 (pt)
KR (1) KR20090114371A (pt)
CN (1) CN101600435A (pt)
AU (1) AU2008211480A1 (pt)
BR (1) BRPI0805841A2 (pt)
CA (1) CA2669563A1 (pt)
EA (1) EA200970720A1 (pt)
MX (1) MX2009008059A (pt)
TW (1) TW200838535A (pt)
WO (1) WO2008093495A1 (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA00004955A (es) * 1997-11-19 2002-10-17 Kowa Co Derivados novedosos de piridazina y medicinas que los contienen como ingredientes activos.
IL154709A0 (en) * 2000-09-18 2003-10-31 Eisai Co Ltd Pyridazinone and triazinone derivatives and pharmaceutical compositions containing the same

Also Published As

Publication number Publication date
CN101600435A (zh) 2009-12-09
JPWO2008093495A1 (ja) 2010-05-20
US20100075972A1 (en) 2010-03-25
WO2008093495A1 (ja) 2008-08-07
MX2009008059A (es) 2009-08-12
KR20090114371A (ko) 2009-11-03
AU2008211480A1 (en) 2008-08-07
EA200970720A1 (ru) 2009-12-30
CA2669563A1 (en) 2008-08-07
TW200838535A (en) 2008-10-01
EP2127653A1 (en) 2009-12-02

Similar Documents

Publication Publication Date Title
CL2018001762A1 (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas. (divisional solicitud 201402087).
BR112015020650A2 (pt) inibidores de histona demetilases
BRPI0717845A2 (pt) Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
SV2009002899A (es) Diarilureas para el tratamiento de la hipertension pulmonar
AR065721A1 (es) Derivados de piridazinona utiles como inhibidores de glucano sintasa. composiciones farmaceuticas.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2007003495A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de la actividad de la akt; composicion farmaceutica; y uso para el tratamiento o prevencion del cancer.
BR112015021352A2 (pt) composições antimicrobianas
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
MX2014002904A (es) Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos.
MX2017007829A (es) Composicion antimicrobiana.
NO20084749L (no) Organiske forbindelser og deres anvendelser
BR112017010439A2 (pt) composto, composição farmacêutica, combinação farmacêutica, kit, métodos para controle de uma doença fúngica em uma planta e para prevenção ou tratamento de doença fúngica em um indivíduo, e, uso de um composto
TW201625535A (en) Inhibitors of histone demethylases
MX362806B (es) Inhibidores biciclicos.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
CL2007002231A1 (es) Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico.
WO2015066302A3 (en) Compositions, methods of use, and methods of treatment
AR091739A1 (es) Composiciones y metodos para reducir el riesgo cardiometabolico
CR10524A (es) Compuesto triciclico y uso farmaceutico del mismo
BR112014011601A2 (pt) bidens pilosa e compostos poliacetilênicos para a prevenção e para o tratamento de coccidiose
BR112013005532A2 (pt) agente terapêutico para dor
WO2022063869A3 (en) Compounds for the treatment of viral infections
CR11439A (es) Composiciones para inhalacion comprendiendo acido montelukast y un inhibidor pde-4 o un corticosteroide inhalado
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 4A ANUIDADE.